PHAXIAM THERAPEUTICS S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.95 EUR | 0.00% |
|
+1.03% | -35.87% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.95
EUR
Average target price
6.85
EUR
Spread / Average Target
+132.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.87% | 19.13M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- Phaxiam Therapeutics Delists from Nasdaq Capital Market
